We are analyzing https://link.springer.com/article/10.1007/s00018-025-05611-1.

Title:
Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches | Cellular and Molecular Life Sciences
Description:
Influenza viruses still represent a great concern for Public Health by causing yearly seasonal epidemics and occasionally worldwide pandemics. Moreover, spillover events at the animal-human interface are becoming more frequent nowadays, also involving animal species not previously found as reservoirs. To restrict the effects of influenza virus epidemics, especially in at-risk population, and to prepare a drug arsenal for possible future pandemics, researchers worldwide have been working on the development of antiviral strategies since the 80’s of the last century. One of the main obstacles is the considerable genomic variability of influenza viruses, which constantly poses the issues of drug-resistance emergence and immune evasion. This review summarizes the approved therapeutics for clinical management of influenza, promising new anti-flu compounds and monoclonal antibodies currently undergoing clinical evaluation, and molecules with efficacy against influenza virus in preclinical studies. Moreover, we discuss some innovative anti-influenza therapeutic approaches such as combination therapies and targeted protein degradation. Given the limited number of drugs approved for influenza treatment, there is a still strong need for novel potent anti-influenza drugs endowed with a high barrier to drug resistance and broad-spectrum activity against influenza viruses of animal origin that may be responsible of future large outbreaks and pandemics.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Video & Online Content

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,734,772 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

pubmed, influenza, article, google, scholar, cas, virus, viral, central, antiviral, inhibitors, clinical, drug, viruses, oseltamivir, activity, host, phase, targeting, chem, antiinfluenza, agents, med, infection, inhibitor, nct, replication, cell, polymerase, vitro, treatment, protein, drugs, efficacy, patients, rna, antibodies, iav, neuraminidase, combination, trial, cellular, human, vivo, potent, therapy, resistance, fig, res, infect,

Topics {✒️}

6-dichloro-1-beta-d-ribo-furanosyl-benzimidazole serine-5-phosphorylated carboxyl-terminal domain raf/mek/erk signalling cascade photo-cross-linked chemical arrays broad-spectrum cycloheptathiophene-3-carboxamide compounds pa–pb1 protein–protein interaction pa-pb1 protein–protein interaction szymańska-de wijs km fluorescence polarization assay β-d-n4-hydroxycytidine overcoming n1–h274y oseltamivir-resistant broad-spectrum anti-influenza activity central cap-binding domain article download pdf oseltamivir-resistant n1–h274y variant ]pyrimidine-2-carboxamide-based compounds targeting te velthuis ajw anti-hemagglutinin stem antibodies monoclonal antibody vis410 vogelzang-van trierum se ikk/nf-kb transcription pathways cross-reactive neutralizing activity unique rna-binding domain anti-m2e monoclonal antibody oseltamivir-resistant na-h274y viruses protein–protein interaction inhibitors n-terminal endonuclease domain protective neuraminidase-reactive antibodies pa c-terminus forms prevent pb1/pb2 heterodimerization develop anti-influenza drugs cellular raf/mek/erk pa/pb1 interaction inhibitors anti-ha stem antibodies pre-existing antineuraminidase antibodies antibody-dependent cellular phagocytosis host-directed agents yielded cellular importin-β ranbp5 ha stem-targeting antibody broad-spectrum influenza antivirals potent broad-spectrum inhibitors rdrp pa/pb1 interaction cell-based systems correlated steroidal anti-inflammatory drug mosquito-borne flaviviruses achieved anti-influenza agents targeting called hydrophobic tagging dual-functioning 5′-ppp-ns1shrna anti-na abs capable broad-spectrum antiviral activity

Questions {❓}

Balzarini J (2007) Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
Mercorelli B, Palù G, Loregian A (2018) Drug repurposing for viral infectious diseases: how far are we?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches
         description:Influenza viruses still represent a great concern for Public Health by causing yearly seasonal epidemics and occasionally worldwide pandemics. Moreover, spillover events at the animal-human interface are becoming more frequent nowadays, also involving animal species not previously found as reservoirs. To restrict the effects of influenza virus epidemics, especially in at-risk population, and to prepare a drug arsenal for possible future pandemics, researchers worldwide have been working on the development of antiviral strategies since the 80’s of the last century. One of the main obstacles is the considerable genomic variability of influenza viruses, which constantly poses the issues of drug-resistance emergence and immune evasion. This review summarizes the approved therapeutics for clinical management of influenza, promising new anti-flu compounds and monoclonal antibodies currently undergoing clinical evaluation, and molecules with efficacy against influenza virus in preclinical studies. Moreover, we discuss some innovative anti-influenza therapeutic approaches such as combination therapies and targeted protein degradation. Given the limited number of drugs approved for influenza treatment, there is a still strong need for novel potent anti-influenza drugs endowed with a high barrier to drug resistance and broad-spectrum activity against influenza viruses of animal origin that may be responsible of future large outbreaks and pandemics.
         datePublished:2025-02-13T00:00:00Z
         dateModified:2025-02-13T00:00:00Z
         pageStart:1
         pageEnd:31
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s00018-025-05611-1
         keywords:
            Avian influenza
            Combination therapy
            Protein–protein interaction inhibitors
            Hemagglutinin
            Neuraminidase
            RNA polymerase
            Monoclonal antibodies
            Targeted protein degradation
            Cell Biology
            Biomedicine
            general
            Life Sciences
            Biochemistry
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00018-025-05611-1/MediaObjects/18_2025_5611_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00018-025-05611-1/MediaObjects/18_2025_5611_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00018-025-05611-1/MediaObjects/18_2025_5611_Fig3_HTML.png
         isPartOf:
            name:Cellular and Molecular Life Sciences
            issn:
               1420-9071
            volumeNumber:82
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Anna Bonomini
               affiliation:
                     name:University of Padua
                     address:
                        name:Department of Molecular Medicine, University of Padua, Padua, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Beatrice Mercorelli
               affiliation:
                     name:University of Padua
                     address:
                        name:Department of Molecular Medicine, University of Padua, Padua, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Arianna Loregian
               url:http://orcid.org/0000-0002-8900-861X
               affiliation:
                     name:University of Padua
                     address:
                        name:Department of Molecular Medicine, University of Padua, Padua, Italy
                        type:PostalAddress
                     type:Organization
                     name:Padua University Hospital
                     address:
                        name:Microbiology and Virology Unit, Padua University Hospital, Padua, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches
      description:Influenza viruses still represent a great concern for Public Health by causing yearly seasonal epidemics and occasionally worldwide pandemics. Moreover, spillover events at the animal-human interface are becoming more frequent nowadays, also involving animal species not previously found as reservoirs. To restrict the effects of influenza virus epidemics, especially in at-risk population, and to prepare a drug arsenal for possible future pandemics, researchers worldwide have been working on the development of antiviral strategies since the 80’s of the last century. One of the main obstacles is the considerable genomic variability of influenza viruses, which constantly poses the issues of drug-resistance emergence and immune evasion. This review summarizes the approved therapeutics for clinical management of influenza, promising new anti-flu compounds and monoclonal antibodies currently undergoing clinical evaluation, and molecules with efficacy against influenza virus in preclinical studies. Moreover, we discuss some innovative anti-influenza therapeutic approaches such as combination therapies and targeted protein degradation. Given the limited number of drugs approved for influenza treatment, there is a still strong need for novel potent anti-influenza drugs endowed with a high barrier to drug resistance and broad-spectrum activity against influenza viruses of animal origin that may be responsible of future large outbreaks and pandemics.
      datePublished:2025-02-13T00:00:00Z
      dateModified:2025-02-13T00:00:00Z
      pageStart:1
      pageEnd:31
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s00018-025-05611-1
      keywords:
         Avian influenza
         Combination therapy
         Protein–protein interaction inhibitors
         Hemagglutinin
         Neuraminidase
         RNA polymerase
         Monoclonal antibodies
         Targeted protein degradation
         Cell Biology
         Biomedicine
         general
         Life Sciences
         Biochemistry
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00018-025-05611-1/MediaObjects/18_2025_5611_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00018-025-05611-1/MediaObjects/18_2025_5611_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00018-025-05611-1/MediaObjects/18_2025_5611_Fig3_HTML.png
      isPartOf:
         name:Cellular and Molecular Life Sciences
         issn:
            1420-9071
         volumeNumber:82
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Anna Bonomini
            affiliation:
                  name:University of Padua
                  address:
                     name:Department of Molecular Medicine, University of Padua, Padua, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Beatrice Mercorelli
            affiliation:
                  name:University of Padua
                  address:
                     name:Department of Molecular Medicine, University of Padua, Padua, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Arianna Loregian
            url:http://orcid.org/0000-0002-8900-861X
            affiliation:
                  name:University of Padua
                  address:
                     name:Department of Molecular Medicine, University of Padua, Padua, Italy
                     type:PostalAddress
                  type:Organization
                  name:Padua University Hospital
                  address:
                     name:Microbiology and Virology Unit, Padua University Hospital, Padua, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cellular and Molecular Life Sciences
      issn:
         1420-9071
      volumeNumber:82
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Padua
      address:
         name:Department of Molecular Medicine, University of Padua, Padua, Italy
         type:PostalAddress
      name:University of Padua
      address:
         name:Department of Molecular Medicine, University of Padua, Padua, Italy
         type:PostalAddress
      name:University of Padua
      address:
         name:Department of Molecular Medicine, University of Padua, Padua, Italy
         type:PostalAddress
      name:Padua University Hospital
      address:
         name:Microbiology and Virology Unit, Padua University Hospital, Padua, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Anna Bonomini
      affiliation:
            name:University of Padua
            address:
               name:Department of Molecular Medicine, University of Padua, Padua, Italy
               type:PostalAddress
            type:Organization
      name:Beatrice Mercorelli
      affiliation:
            name:University of Padua
            address:
               name:Department of Molecular Medicine, University of Padua, Padua, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Arianna Loregian
      url:http://orcid.org/0000-0002-8900-861X
      affiliation:
            name:University of Padua
            address:
               name:Department of Molecular Medicine, University of Padua, Padua, Italy
               type:PostalAddress
            type:Organization
            name:Padua University Hospital
            address:
               name:Microbiology and Virology Unit, Padua University Hospital, Padua, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Molecular Medicine, University of Padua, Padua, Italy
      name:Department of Molecular Medicine, University of Padua, Padua, Italy
      name:Department of Molecular Medicine, University of Padua, Padua, Italy
      name:Microbiology and Virology Unit, Padua University Hospital, Padua, Italy

External Links {🔗}(1562)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

7.35s.

LINK . SPRINGER . COM {}